RecruitingPhase 2Phase 3NCT05749289
Application of Al18F-octreotide PET/CT in Tumors With Positive SSTR Expression
Sponsor
Cancer Institute and Hospital, Chinese Academy of Medical Sciences
Enrollment
400 participants
Start Date
Dec 20, 2022
Study Type
INTERVENTIONAL
Conditions
Summary
This is an open-label whole-body PET/CT study for investigating the value of Al18F-octreotide PET/CT in patients with SSTR positive tumors
Eligibility
Min Age: 18 Years
Plain Language Summary
Simplified for easier understanding
This clinical trial is studying a drug called Al18F-octreotide for people with sstr positive tumors. The study is currently recruiting participants at 1 location. People eligible for this study include aged 18 Years and older.
This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.
Interested in this trial?
Get notified about updates and connect with the research team.
Interventions
DRUGAl18F-octreotide
Al18F-octreotide I was injected into the patients before the PET/CT scans
Locations(1)
View Full Details on ClinicalTrials.gov
For the most up-to-date information, visit the official listing.
NCT05749289